Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aeromics, Inc. is a clinical-stage pharmaceutical company developing an intravenously administered aquaporin-4 (AQP4) inhibitor (AER-271) for severe, acute ischemic stroke that will prevent or arrest brain swelling (cerebral edema) following an ischemic event. By preventing brain swelling AER-271 will significantly improve survival following an ischemic brain event, lead to better outcomes and more complete and faster recovery...
Aeromics, Inc. is a clinical-stage pharmaceutical company developing an intravenously administered aquaporin-4 (AQP4) inhibitor (AER-271) for severe, acute ischemic stroke that will prevent or arrest brain swelling (cerebral edema) following an ischemic event. By preventing brain swelling AER-271 will significantly improve survival following an ischemic brain event, lead to better outcomes and more complete and faster recovery and reduce the need for more invasive treatments such as decompressive craniectomy. Aeromics is currently investigating the pharmacokinetics, safety and tolerability of AER-271 in a Phase 1 clinical trial.

List your booth number for exhibitions, ask us